摘要
我国创新药物可及性现状严峻,对患者、药品生产企业、医药行业影响巨大,有必要将创新药物纳入医疗保障范围,以提高其可及性。财政对于创新药物的承受力,以及临床实践中创新所获得的健康结果是否符合其预期价值,是将创新药物纳入医疗保障体系的重要考量因素。国内外的实践表明,可以通过谈判机制、药品风险共担方案、实行灵活的保障水平等方法加以解决。
The problems of accessibility of innovative drugs in China have brought significant influence on patients, pharmaceutical production enterprises and pharmaceutical industry. It is necessary to involve innovative drugs into medical security system to improve the accessibility of innovative drugs. Important considerations include the financial affordability and health outcomes of innovative drugs. Domestic and international practices showed that negotiation mechanism, drug risk sharing scheme and flexible insurance were effective methods.
出处
《中国卫生事业管理》
北大核心
2017年第2期128-130,156,共4页
Chinese Health Service Management
基金
广东省哲学社会科学"十二五"2015年度规划项目一般项目"重大医疗保险的创新药物准入机制研究""(编号:GD15CGL01)
2015年度广东医学院科研基金人文社科类重点培育项目"重大医疗保险的创新药物准入机制研究"(编号:Z2015008)
关键词
创新药物
可及性
医疗保障
谈判机制
风险分担协议
innovative drugs
accessibility
medical security
negotiation mechanism
risk sharing scheme.
